CT-1 may serve as a novel cardioprotective agent if its hypertrophic effects, mediated by a distinct signaling pathway, can be specifically inhibited.
Cardiotrophin-1 (CT-1) is a member of the IL-6 family of cytokines which was originally discovered as a factor which can induce hypertrophy of cardiac myocytes both in vitro and in vivo. Subsequently, CT-1 has been shown to have a wide variety of different effects on cardiac and non cardiac cells including the ability to stimulate the survival of both cardiac and neuronal cells. Interestingly, whilst activation of the p42/p44 MAP kinase pathway is necessary for the survival promoting effects of CT-1 in cardiac cells, it is not required for its hypertrophic effect which is likely to involve activation of the Jak/STAT-3 pathway. CT-1 may therefore be of use as a novel cardio-protective agent, particularly if its hypertrophic effect can be specifically inhibited.
No takes yet. Share an insight, caveat, or question.
David S. Latchman (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: